ST
VIRX

Spot Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Spot Trading’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-240
Closed -$360K – 4476
2014
Q3 		$360K Buy
+240
New +$347K ﹤0.01% 2791

Other funds holding VIRX

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Spot Trading's VIRX Position: Q3 2015 in Review

Spot Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 92 shares — an estimated $58K sold.

Spot Trading first reported a position in VIRX in Q2 2014 and held it in 3 quarters. The position peaked at $202K in Q2 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

  • Spot Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Spot Trading sold 92 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $58K.
  • Spot Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • Spot Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $202K in Q2 2014.
  • 59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Spot Trading's 13F filing for Q3 2015, filed 3 Nov 2015.